Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

AI-ECHO Hemodynamic Phenotyping in Septic Shock

AI-ECHO-Based Intelligent Hemodynamic Subtyping and Dynamic Evolution in Septic Shock: A Prospective Observational Cohort Study

This is a prospective, single-center, observational cohort study. The purpose of this study is to investigate the hemodynamic heterogeneity and dynamic evolution patterns in patients with septic shock, using point-of-care echocardiography combined with artificial intelligence technology. The study will enroll 240 adult patients with septic shock admitted to the ICU. Standardized cardiac ultrasound examinations will be performed at multiple time points, and multi-dimensional clinical-echocardiographic data will be collected. An AI-based automatic echocardiographic analysis system will be developed, and unsupervised machine learning will be applied to identify distinct hemodynamic subtypes and their dynamic evolution trajectories. This study aims to provide innovative solutions for individualized and precise hemodynamic management of septic shock.

Visão geral do estudo

Status

Ainda não está recrutando

Intervenção / Tratamento

Descrição detalhada

Background

Septic shock is the most severe stage of sepsis and is associated with mortality as high as 40%-50%. Its pathophysiological core involves profound hemodynamic disturbances resulting from complex interactions among abnormal vascular tone, relative or absolute intravascular volume deficiency, myocardial depression, and microcirculatory dysfunction.

Accumulating evidence has demonstrated substantial heterogeneity in hemodynamic profiles among patients with septic shock, including hyperdynamic states, left ventricular systolic or diastolic dysfunction, right ventricular dysfunction, and various combined phenotypes. The traditional binary classification of "warm shock" versus "cold shock" is too simplistic to capture this complexity. Such heterogeneity may partly explain why uniform treatment strategies, such as early goal-directed therapy, have yielded inconsistent results and may cause iatrogenic harm in certain subgroups.

Echocardiography has become an important tool for hemodynamic assessment in the intensive care unit (ICU). It enables noninvasive, real-time evaluation of cardiac structure and function, including left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), right ventricular function, diastolic function, cardiac output, and volume status. However, its clinical utility is limited by:

  • High operator dependency and interobserver variability;
  • Time-consuming post-processing and interpretation;
  • Difficulty in performing frequent dynamic assessments in busy ICU settings; and
  • Limited integrated analysis of multiple parameters over time.

Recent advances in artificial intelligence (AI), particularly deep learning, have shown considerable promise in medical image analysis. In echocardiography, AI has demonstrated promising performance in view classification, cardiac structure segmentation, and automated measurement of functional parameters. Meanwhile, unsupervised machine learning methods provide potential approaches for identifying disease subtypes from high-dimensional clinical data.

Building on the established "Guangzhou Sepsis Cohort" and prior research experience in AI-assisted critical care medicine, this study will integrate AI and echocardiography to systematically characterize hemodynamic phenotypes and their dynamic evolution in patients with septic shock.

Study Design

This is a prospective, single-center, observational cohort study. A total of 360 adults with septic shock admitted to the ICU of The Second Affiliated Hospital of Guangzhou Medical University are anticipated to be consecutively enrolled.

Echocardiographic examinations will be performed on Day 1, Day 3, and Day 7 after enrollment. Clinical data, laboratory measurements, treatment information, and clinical outcomes will be collected according to the study protocol.

At each echocardiographic time point, standardized point-of-care echocardiography will be performed using the same model of ultrasound system and a phased-array transducer. Cine loops of the apical four-chamber, two-chamber, and three-chamber views will be acquired for at least three cardiac cycles. Additional Doppler, M-mode, right ventricular-focused, left ventricular outflow tract, and inferior vena cava recordings will be acquired as required for the prespecified echocardiographic measurements and as detailed in the imaging manual. All images will be stored in de-identified DICOM format using a unique study identification code.

AI-derived measurements will be used for research purposes only and will not guide clinical management. Clinical treatment will be determined by the treating clinical team and will not be assigned by the study.

Clinical data collected at or near the echocardiographic examinations will include vital signs, laboratory measurements, fluid balance, vasopressor dosage, and other treatment information. Blood samples will be collected on Day 1, Day 3, and Day 7 for targeted proteomic and metabolomic analyses, as specified in the study protocol.

Study Objectives

Primary Objective:

To identify and characterize distinct hemodynamic subtypes of septic shock using an unsupervised Gaussian mixture model based on prespecified multidimensional echocardiographic parameters.

Secondary Objectives:

• Longitudinal changes and dynamic evolution of hemodynamic status within 7 days after enrollment;

  • Associations of hemodynamic phenotypes with clinical severity and clinical outcomes;
  • Agreement between AI-derived and blinded expert echocardiographic measurements;
  • Exploratory associations of targeted proteomic and metabolomic profiles with hemodynamic phenotypes; and
  • Exploratory development and internal validation of an early-warning model for 28-day all-cause mortality.

Study Population

Adults (≥18 years) with septic shock, diagnosed according to the Sepsis-3 criteria, who meet the eligibility criteria listed in the Eligibility section will be consecutively enrolled from the ICU of The Second Affiliated Hospital of Guangzhou Medical University. Eligible participants must have an expected ICU stay of at least 72 hours, and written informed consent must be obtained from the patient or a legally authorized representative.

Outcome Measures

Primary Outcome:

Hemodynamic subtypes identified using an unsupervised Gaussian mixture model based on prespecified multidimensional echocardiographic parameters collected within 7 days after enrollment.

Secondary Outcomes:

  • Agreement between AI-derived echocardiographic measurements and blinded expert reference measurements, evaluated using intraclass correlation coefficients and Bland-Altman analyses;
  • Associations between hemodynamic subtypes and 28-day mortality;
  • Associations between hemodynamic subtypes and organ failure severity, as assessed by the Sequential Organ Failure Assessment (SOFA) score;
  • Duration of vasopressor use; and
  • ICU and hospital lengths of stay.

Statistical Analysis

Sample Size Considerations: The planned enrollment of 240 participants is based on the anticipated number of eligible septic shock admissions during the recruitment period, expected consent and follow-up completion, and study feasibility. The target sample size is intended to provide an adequate dataset for exploratory hemodynamic phenotyping and longitudinal echocardiographic analyses. As the primary objective is exploratory hemodynamic phenotyping using unsupervised analysis, no formal hypothesis-based power calculation was performed. Analyses of clinical outcomes, multi-omics profiles, and early-warning models will be considered exploratory, and model complexity will be limited according to the effective sample size and number of observed events.

Continuous variables will be summarized as mean ± standard deviation or median with interquartile range, as appropriate. Categorical variables will be summarized as frequencies and percentages.

An unsupervised Gaussian mixture model will be applied to identify hemodynamic subtypes based on prespecified echocardiographic parameters. Clinical characteristics, treatment information, and outcomes will be compared among the identified subtypes.

Agreement between AI-derived measurements and blinded expert reference measurements will be evaluated using intraclass correlation coefficients and Bland-Altman analyses. Targeted proteomic and metabolomic analyses will evaluate associations between protein or metabolite abundances and hemodynamic phenotype membership using methods appropriate for high-dimensional data. Where applicable, the false discovery rate will be used to account for multiple comparisons. These analyses will be considered exploratory.

An exploratory early-warning model for 28-day all-cause mortality will be developed using prespecified candidate predictors. Model discrimination will be assessed using the area under the receiver operating characteristic curve, and calibration will be evaluated using calibration plots and calibration statistics. Internal validation will be performed using bootstrap resampling or cross-validation. The number of candidate predictors and model complexity will be limited according to the number of observed events to reduce the risk of overfitting.

Multivariable logistic regression or Cox proportional hazards models will be constructed, as appropriate, to explore factors associated with adverse clinical outcomes. Repeated measurements and missing data will be addressed according to the prespecified statistical analysis plan.

Statistical analyses will be performed using SPSS, R, and Python. A two-sided P value <0.05 will be considered statistically significant, with exploratory analyses interpreted accordingly.

Tipo de estudo

Observacional

Inscrição (Estimado)

240

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Weiyan Chen, MD, PhD
  • Número de telefone: +86 13751845652
  • E-mail: sam11124@163.com

Estude backup de contato

  • Nome: Lili Tao, MD
  • Número de telefone: +86 020-34153246
  • E-mail: taollicu@163.com

Locais de estudo

    • Guangdong
      • Guangzhou, Guangdong, China, 511436
        • The Second Affiliated Hospital of Guangzhou Medical University
        • Contato:
          • Weiyan Chen, MD, PhD
          • Número de telefone: +86 13751845652
          • E-mail: sam11124@163.com
        • Contato:
        • Investigador principal:
          • Weiyan Chen, MD, PhD
        • Subinvestigador:
          • Lili Tao, MD
        • Subinvestigador:
          • Sihong Xie, PhD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

This is a prospective observational cohort study enrolling adult patients with septic shock admitted to the ICU. The study aims to construct a multi-dimensional clinical-echocardiographic database, develop an AI-based automatic echocardiographic analysis system, identify hemodynamic subtypes using unsupervised machine learning, and reveal the dynamic evolution patterns of hemodynamics in septic shock.

Descrição

Inclusion Criteria:

  1. Age ≥18 years.
  2. Confirmed diagnosis of septic shock according to the Sepsis-3 criteria.
  3. Expected ICU stay of at least 72 hours.
  4. Written informed consent obtained from the patient or legally authorized representative.

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded:

  1. Severe chronic heart disease, such as severe valvular heart disease or chronic heart failure with left ventricular ejection fraction (LVEF) <30%.
  2. Acute coronary syndrome.
  3. Status post cardiac surgery.
  4. Pregnancy.
  5. Inability to obtain high-quality echocardiographic images at screening.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Septic Shock Patients

Adults with septic shock admitted to the intensive care unit who meet the eligibility criteria listed in the Eligibility section. Participants will undergo standardized point-of-care echocardiography on Day 1, Day 3, and Day 7 after enrollment, together with clinical data and blood sample collection as specified in the study protocol. Clinical management will be determined by the treating clinical team and will not be assigned by the study. AI-derived echocardiographic measurements will be used for research purposes only and will not guide clinical management.

Standardized point-of-care echocardiography will be performed on Day 1, Day 3, and Day 7 after enrollment. Images will be acquired according to the imaging manual and stored in de-identified DICOM format using a unique study identification code. Echocardiographic parameters will be used for hemodynamic phenotyping and assessment of changes over time.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Echocardiography-Derived Hemodynamic Phenotypes in Adults With Septic Shock
Prazo: Within 7 days after enrollment

Identification and characterization of distinct hemodynamic phenotypes in adults with septic shock using unsupervised analysis of prespecified multidimensional echocardiographic parameters. The parameters may include measures of left ventricular systolic and diastolic function, right ventricular function, cardiac output or flow, and inferior vena cava dynamics, depending on data availability and image quality. The number and characteristics of the identified phenotypes will be determined using prespecified model selection and evaluation procedures.

Within 7 days after enrollment

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Longitudinal Changes and Dynamic Evolution of Hemodynamic Status
Prazo: Day 1, Day 3, and Day 7 after enrollment.

Serial changes in echocardiographic parameters and transitions among hemodynamic phenotypes will be evaluated during follow-up.

Day 1, Day 3, and Day 7 after enrollment.
Associations Between Hemodynamic Phenotypes and Clinical Severity and Outcomes
Prazo: Within 7 days after enrollment for severity measures; up to 28 days or during the index hospitalization for clinical outcomes.

Associations of hemodynamic phenotypes with SOFA score, blood lactate, 28-day all-cause mortality, vasopressor duration, and ICU and hospital length of stay will be evaluated.

Within 7 days after enrollment for severity measures; up to 28 days or during the index hospitalization for clinical outcomes.
Agreement Between AI-Derived and Blinded Expert Echocardiographic Measurements
Prazo: Day 1, Day 3, and Day 7 after enrollment.

Agreement for prespecified echocardiographic parameters will be evaluated using intraclass correlation coefficients and Bland-Altman analyses.

Day 1, Day 3, and Day 7 after enrollment.
Associations Between Molecular Profiles and Hemodynamic Phenotypes
Prazo: Day 1, Day 3, and Day 7 after enrollment.

Exploratory associations of targeted proteomic and metabolomic profiles with hemodynamic phenotypes will be evaluated.

Day 1, Day 3, and Day 7 after enrollment.
Exploratory Early-Warning Model for 28-Day All-Cause Mortality
Prazo: Predictors within 7 days; mortality through 28 days after enrollment.

An exploratory model will be developed and internally validated using clinical and echocardiographic data.

Predictors within 7 days; mortality through 28 days after enrollment.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Weiyan Chen, MD, PhD, Second Affiliated Hospital of Guangzhou Medical University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

30 de novembro de 2026

Conclusão Primária (Estimado)

9 de novembro de 2028

Conclusão do estudo (Estimado)

30 de novembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

25 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de novembro de 2026

Primeira postagem (Real)

9 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

9 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever